Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2018 2
2020 2
2021 3
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Among authors: fossard g. Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642. Blood. 2022. PMID: 35609174 Free PMC article.
Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.
Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, Hayette S, Tigaud I, Plesa A, Labussiere-Wallet H, Sobh M, Michallet AS, Marie B, Nicolini FE, Guillermin Y, Gaëlle F, Lebras L, Rey P, Jauffret-Bertholon L, Laude MC, Sandrine L, Michallet M. Belhabri A, et al. Among authors: gaelle f. Cancer Med. 2023 Aug;12(16):16929-16944. doi: 10.1002/cam4.6322. Epub 2023 Aug 7. Cancer Med. 2023. PMID: 37548369 Free PMC article.
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, Yakoub-Agha I, Srour M, Bulabois CE, Huynh A, Chantepie S, Menard AL, Rubio MT, Ceballos P, Dulery R, Furst S, Malard F, Blaise D, Mohty M. Brissot E, et al. Among authors: fossard g. Blood Cancer J. 2024 Feb 19;14(1):31. doi: 10.1038/s41408-024-00990-3. Blood Cancer J. 2024. PMID: 38374026 Free PMC article. Clinical Trial.
Lung cancer may increase serum procalcitonin level.
Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, Desseigne M, Freymond N, Geriniere L, Perrot E, Souquet PJ, Couraud S. Avrillon V, et al. Among authors: fossard g. Infect Disord Drug Targets. 2015;15(1):57-63. doi: 10.2174/1871526515666150320162950. Infect Disord Drug Targets. 2015. PMID: 25809625
Distinct Immune Reconstitution Profiles Captured by Immune Functional Assays at 6 Months Post Allogeneic Hematopoietic Stem Cell Transplantation.
Mouton W, Conrad A, Alcazer V, Boccard M, Bodinier M, Oriol G, Subtil F, Labussière-Wallet H, Ducastelle-Lepretre S, Barraco F, Balsat M, Fossard G, Brengel-Pesce K, Ader F, Trouillet-Assant S. Mouton W, et al. Among authors: fossard g. Transplant Cell Ther. 2023 Feb;29(2):94.e1-94.e13. doi: 10.1016/j.jtct.2022.10.025. Epub 2022 Nov 3. Transplant Cell Ther. 2023. PMID: 36336259 Free article.
Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study.
Laurino M, Loron S, Larcher MV, Fossard G, Elhamri M, Deloire A, Balsat M, Barraco F, Labussière H, Ducastelle S, Renault M, Wattel E, Heiblig M, Salles G, Thomas X. Laurino M, et al. Among authors: fossard g. Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020020. doi: 10.4084/MJHID.2020.020. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 32395209 Free PMC article.
Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Daull AM, Dubois V, Labussière-Wallet H, Venet F, Barraco F, Ducastelle-Lepretre S, Larcher MV, Balsat M, Gilis L, Fossard G, Ghesquières H, Heiblig M, Ader F, Alcazer V. Daull AM, et al. Among authors: fossard g. Front Immunol. 2022 Mar 4;13:841470. doi: 10.3389/fimmu.2022.841470. eCollection 2022. Front Immunol. 2022. PMID: 35309346 Free PMC article.
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Plesa A, Roumier C, Gutrin J, Larcher MV, Balsat M, Cadassou O, Barraco F, Fossard G, Baudouin A, Labussière H, Tigaud I, Ducastelle S, Hayette S, Sujobert P, Heiblig M, Elhamri M, Thomas X. Plesa A, et al. Among authors: fossard g. Leuk Res. 2021 Dec;111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26. Leuk Res. 2021. PMID: 34364023 No abstract available.
18 results